Oculis (OCS) Competitors $18.50 +0.07 (+0.38%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. VKTX, PTGX, MLTX, MTSR, KYMR, IMVT, MOR, CRNX, ALVO, and HCMShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Viking Therapeutics (VKTX), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Kymera Therapeutics (KYMR), Immunovant (IMVT), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors Viking Therapeutics Protagonist Therapeutics MoonLake Immunotherapeutics Metsera Kymera Therapeutics Immunovant MorphoSys Crinetics Pharmaceuticals Alvotech HUTCHMED Viking Therapeutics (NASDAQ:VKTX) and Oculis (NASDAQ:OCS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Is VKTX or OCS more profitable? Viking Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. Viking Therapeutics' return on equity of -14.41% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -14.41% -14.02% Oculis -13,788.70%-92.95%-70.03% Does the media favor VKTX or OCS? In the previous week, Viking Therapeutics had 6 more articles in the media than Oculis. MarketBeat recorded 10 mentions for Viking Therapeutics and 4 mentions for Oculis. Viking Therapeutics' average media sentiment score of 0.42 beat Oculis' score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of VKTX or OCS? 76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 4.1% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, VKTX or OCS? Oculis has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.15-27.21Oculis$780K1,029.93-$97.43M-$2.64-6.97 Which has more volatility & risk, VKTX or OCS? Viking Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Do analysts recommend VKTX or OCS? Viking Therapeutics presently has a consensus target price of $87.15, suggesting a potential upside of 178.54%. Oculis has a consensus target price of $35.33, suggesting a potential upside of 92.03%. Given Viking Therapeutics' higher probable upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryViking Therapeutics beats Oculis on 12 of the 15 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$804.70M$2.96B$5.56B$9.04BDividend YieldN/A2.42%5.25%4.03%P/E Ratio-6.978.0519.5820.23Price / Sales1,029.93296.11442.27127.79Price / CashN/A42.7337.5058.41Price / Book9.637.748.085.60Net Income-$97.43M-$54.96M$3.16B$248.43M7 Day Performance-2.93%6.04%3.77%5.15%1 Month Performance-7.02%4.47%3.90%7.62%1 Year Performance64.29%6.12%34.22%21.56% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis1.7453 of 5 stars$18.40-0.2%$35.33+92.0%+67.4%$804.70M$780K-6.972News CoverageVKTXViking Therapeutics3.9825 of 5 stars$27.51-2.4%$87.15+216.8%-43.9%$3.17BN/A-23.9220PTGXProtagonist Therapeutics2.4803 of 5 stars$49.87-2.3%$66.10+32.5%+51.6%$3.16B$434.43M66.49120News CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.9544 of 5 stars$47.50-2.8%$74.50+56.8%+7.5%$3.13BN/A-20.652News CoveragePositive NewsMTSRMetseraN/A$28.39-3.6%$55.00+93.7%N/A$3.09BN/A0.0081News CoverageKYMRKymera Therapeutics3.164 of 5 stars$43.81-2.2%$59.11+34.9%+14.6%$2.92B$47.07M-14.13170Analyst RevisionIMVTImmunovant1.7315 of 5 stars$16.42-3.1%$38.33+133.5%-41.8%$2.90BN/A-5.99120Analyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.4517 of 5 stars$29.06-2.5%$71.75+146.9%-33.0%$2.79B$1.04M-7.61210News CoverageAnalyst ForecastALVOAlvotech3.5074 of 5 stars$9.02-1.8%$18.00+99.6%-27.2%$2.77B$491.98M24.381,032Trending NewsHCMHUTCHMED1.7345 of 5 stars$15.42-2.5%$19.00+23.2%-3.3%$2.76B$630.20M0.001,811 Related Companies and Tools Related Companies VKTX Competitors PTGX Competitors MLTX Competitors MTSR Competitors KYMR Competitors IMVT Competitors MOR Competitors CRNX Competitors ALVO Competitors HCM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCS Stock Alerts